Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Beta-O2 announced today that the first patient participating in the company's first broad study of the ßAir Bio-Artificial Pancreas has been successfully implanted. ßAir is in development as a treatment and a potential cure for type 1 diabetes (T1D). Approximately 3 million people have T1D in the U.S.
Eight participants who meet the study criteria will be enrolled in the trial at Uppsala University Hospital in Sweden. Last month, JDRF awarded Beta-O2 a grant to fund half of the $1M, two-year, open label, pilot investigation which will evaluate the safety and efficacy of implanting the ßAir macro-encapsulation with human islets of Langerhans.
http://www.prnewswire.com/news-rele...l-pancreas-for-type-1-diabetes-279886042.html
Eight participants who meet the study criteria will be enrolled in the trial at Uppsala University Hospital in Sweden. Last month, JDRF awarded Beta-O2 a grant to fund half of the $1M, two-year, open label, pilot investigation which will evaluate the safety and efficacy of implanting the ßAir macro-encapsulation with human islets of Langerhans.
http://www.prnewswire.com/news-rele...l-pancreas-for-type-1-diabetes-279886042.html
